HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution.

AuthorsElisabetta Buscarini, Guido Manfredi, Alessandro Zambelli
JournalLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (Liver Transpl) Vol. 14 Issue 11 Pg. 1685-6; author reply 1687-8 (Nov 2008) ISSN: 1527-6473 [Electronic] United States
PMID18975280 (Publication Type: Comment, Letter)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Hemodynamics
  • Humans
  • Liver Diseases (drug therapy)
  • Telangiectasia, Hereditary Hemorrhagic (drug therapy)
  • Treatment Outcome
  • Vascular Malformations (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: